ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Massachusetts » Pulmonary Disease

Top Pulmonary Disease Prescribers in Massachusetts

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
CURTIS MELLO MD

Pulmonary Disease

20,926

$1.41M

641
493 are 65+

8%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 58%

$67
Average prescription price

Avg: $138

DANIEL MARTIN MD

Pulmonary Disease

10,734

$631K

539
408 are 65+

11%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 58%

$59
Average prescription price

Avg: $138

ANAS WARDEH M.D.

Pulmonary Disease

10,144

$1.77M

9336
8177 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

97%
prescriptions for brand name drugs

Avg: 58%

$174
Average prescription price

Avg: $138

MATTHEW MESSINA M.D.

Pulmonary Disease

9,628

$555K

558
475 are 65+

7%
patients receiving schedule two controlled substances

Avg: 1%

5%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 58%

$58
Average prescription price

Avg: $138

JAHN POTHIER M.D.

Pulmonary Disease

8,570

$515K

465
387 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

2%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 58%

$60
Average prescription price

Avg: $138

CHRISTOS KAPOGIANNIS MD

Pulmonary Disease

7,430

$793K

462
269 are 65+

6%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 58%

$107
Average prescription price

Avg: $138

THIRUPAIMARUTH RAMAN MD

Pulmonary Disease

7,203

$463K

284
178 are 65+

24%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 58%

$64
Average prescription price

Avg: $138

ALBERT BARROWS M.D.

Pulmonary Disease

7,126

$511K

533
474 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

2%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 58%

$72
Average prescription price

Avg: $138

RONALD DORRIS MD

Pulmonary Disease

5,919

$466K

235
159 are 65+

9%
patients receiving schedule two controlled substances

Avg: 1%

18%
patients receiving schedule three controlled substances

Avg: 1%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 58%

$79
Average prescription price

Avg: $138

ALEXANDER LATTY M.D.

Pulmonary Disease

5,599

$291K

205
178 are 65+

11%
patients receiving schedule two controlled substances

Avg: 1%

15%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 58%

$52
Average prescription price

Avg: $138

MOHAMMAD REDA M.D.

Pulmonary Disease

5,511

$373K

338
263 are 65+

6%
patients receiving schedule two controlled substances

Avg: 1%

7%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 58%

$68
Average prescription price

Avg: $138

JOHN WENGRYN M.D.

Pulmonary Disease

5,190

$376K

322
257 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

5%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 58%

$72
Average prescription price

Avg: $138

CHARLES WICKS M.D.

Pulmonary Disease

5,151

$326K

334
244 are 65+

7%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 58%

$63
Average prescription price

Avg: $138

K.V.R MOHAN RAO MD

Pulmonary Disease

5,043

$287K

187
147 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 58%

$57
Average prescription price

Avg: $138

CLIFFORD RISK M.D., PH.D.

Pulmonary Disease

4,918

$385K

216
157 are 65+

8%
patients receiving schedule two controlled substances

Avg: 1%

11%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 58%

$78
Average prescription price

Avg: $138

NICK MUCCIARDI MD

Pulmonary Disease

4,886

$527K

361
268 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 58%

$108
Average prescription price

Avg: $138

SHAMIM NAJEEBI MD

Pulmonary Disease

4,871

$894K

561
385 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

77%
prescriptions for brand name drugs

Avg: 58%

$184
Average prescription price

Avg: $138

KENNETH EINSTEIN M.D.

Pulmonary Disease

4,804

$273K

214
189 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

7%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 58%

$57
Average prescription price

Avg: $138

GERMAN IOSIF M.D.

Pulmonary Disease

4,678

$428K

325
215 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

39%
prescriptions for brand name drugs

Avg: 58%

$91
Average prescription price

Avg: $138

CHARLES RANDALL M.D.

Pulmonary Disease

4,588

$401K

384
288 are 65+

6%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 58%

$87
Average prescription price

Avg: $138

JAMES WARGOVICH M.D.

Pulmonary Disease

4,180

$313K

320
255 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 58%

$75
Average prescription price

Avg: $138

STANLEY GLASSER MD

Pulmonary Disease

3,870

$184K

207
167 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 58%

$47
Average prescription price

Avg: $138

EMMET EBY MD

Pulmonary Disease

3,818

$311K

230
172 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 58%

$81
Average prescription price

Avg: $138

SUSAN MEYER N.P.

Pulmonary Disease

3,716

$211K

331
272 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

5%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 58%

$57
Average prescription price

Avg: $138

PETER OSTROW MD

Pulmonary Disease

3,586

$285K

294
261 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 58%

$80
Average prescription price

Avg: $138

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank